Morgan Stanley assumed coverage of Sight Sciences (SGHT) with an Equal Weight rating and a price target of $4, down from $5. The firm sees valuations as “fair” for what it calls a “recovery story following reimbursement challenges.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences price target lowered to $5 from $7 at Morgan Stanley
- Sight Sciences price target lowered to $5.50 from $6 at Piper Sandler
- Sight Sciences Reports Modest Growth and Optimistic Outlook
- Sight Sciences backs FY24 revenue view, sees operating expenses down 4%-6%
- Sight Sciences reports Q3 EPS (22c), consensus (21c)